-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Hjcrzov/tqk35XEIUFVsHjSGo5GQxakzlcOIlcwvKKKeBM9JOB5rDu05gpqrhSjU KTs0idfOM/A7rpYaQePxZg== 0000893838-97-000039.txt : 19970423 0000893838-97-000039.hdr.sgml : 19970423 ACCESSION NUMBER: 0000893838-97-000039 CONFORMED SUBMISSION TYPE: SC 13D PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19970421 SROS: NASD SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: NEUROGEN CORP CENTRAL INDEX KEY: 0000849043 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 222845714 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D SEC ACT: 1934 Act SEC FILE NUMBER: 005-41776 FILM NUMBER: 97584294 BUSINESS ADDRESS: STREET 1: 35 NORTHEAST INDUSTRIAL RD CITY: BRANFORD STATE: CT ZIP: 06405 BUSINESS PHONE: 2034888201 MAIL ADDRESS: STREET 1: 35 NORTHEAST INDUSTRIAL RD CITY: BRANFORD STATE: CT ZIP: 06405 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: FOUR PARTNERS CENTRAL INDEX KEY: 0000942714 STANDARD INDUSTRIAL CLASSIFICATION: [] STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D BUSINESS ADDRESS: STREET 1: 867 MADISON AVENUE STREET 2: C/O B L BLOOM CITY: NEW YORK STATE: NY ZIP: 10021 BUSINESS PHONE: 2125452930 SC 13D 1 SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.___)* Neurogen Corporation - -------------------------------------------------------------------------------- (Name of Issuer) Common Stock, $.025 par value - -------------------------------------------------------------------------------- (Title of Class of Securities) 64124E106 - -------------------------------------------------------------------------------- (CUSIP Number) Thomas J. Tisch 667 Madison Avenue New York, NY 10021 (212) 545-2927 - -------------------------------------------------------------------------------- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) April 11, 1997 - -------------------------------------------------------------------------------- (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box |_| Note: Six copies of this statement, including all exhibits, should be filed with the Commission. See Rule 13d-1(a) for other parties to whom copies are to be sent. *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). SCHEDULE 13D - ------------------- ------------------ CUSIP No. 64124E106 Page 2 of 10 Pages - -------------------- ------------------ - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Four Partners - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) |_| (b) |_| - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS* WC - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) |_| - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION New York - -------------------------------------------------------------------------------- NUMBER OF 7 SOLE VOTING POWER SHARES 771,900 ------------------------------------------------------------- BENEFICIALLY 8 SHARED VOTING POWER OWNED BY -0- ------------------------------------------------------------- EACH 9 SOLE DISPOSITIVE POWER REPORTING 771,900 PERSON ------------------------------------------------------------- 10 SHARED DISPOSITIVE POWER WITH -0- - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 771,900 - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* |_| - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 5.4% - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON* PN - -------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7 (INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION. - -------------------------------------------------------------------------------- CUSIP NO. 64124E106 13D Page 3 of 10 Pages - -------------------------------------------------------------------------------- Item 1. Security and Issuer. ------------------- This Statement relates to the Common Stock, $.025 par value per share (the "Common Stock"), of Neurogen Corporation (the "Issuer"). The principal executive offices of the Issuer are located at 35 Northeast Industrial Road, Branford, Connecticut 06405. Item 2. Identity and Background. ----------------------- This statement is being filed by Four Partners, a New York general partnership ("FP"). The principal business of FP is investments. The address of the principal business and the principal office of FP is c/o Thomas J. Tisch, 667 Madison Avenue, New York, New York 10021. The sole partners of FP are Andrew H. Tisch 1991 Trust, for which Andrew H. Tisch is the managing trustee, Daniel R. Tisch 1991 Trust, for which Daniel R. Tisch is the managing trustee, James S. Tisch 1991 Trust, for which James S. Tisch is the managing trustee, and Thomas J. Tisch 1991 Trust, for which Thomas J. Tisch is the managing trustee. Thomas J. Tisch has been appointed the Manager of FP. Set forth below is certain information with respect to Andrew H. Tisch, Daniel R. Tisch, James S. Tisch and Thomas J. Tisch (the "Messrs. Tisch"), who are the respective managing trustees of the four partners of FP: - -------------------------------------------------------------------------------- CUSIP NO. 64124E106 13D Page 4 of 10 Pages - -------------------------------------------------------------------------------- Name Business Address Present Principal Occupation - ---- ---------------- ----------------------------- Andrew H. Tisch 667 Madison Avenue Member, Management New York, NY 10021 Committee, Loews Corporation (a public company primarily engaged in insurance and tobacco) Daniel R. Tisch c/o Mentor Partners, L.P. General Partner, Mentor 499 Park Avenue Partners, L.P.(a partnership New York, NY 10022 engaged in investment activities) James S. Tisch 667 Madison Avenue President and Chief Operating New York, NY 10021 Officer, Loews Corporation (a public company primarily engaged in insurance and tobacco) Thomas J. Tisch 667 Madison Avenue Managing Partner of FLF New York, NY 10021 Associates and Manager of FP (partnerships engaged in investment activities) The Messrs. Tisch are brothers and are United States citizens. During the last five years, none of the persons or the entities named in this Item 2 has been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors), and none of the persons or the entities named in this Item 2 has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction resulting in its or his being subject to a judgment, decree or - -------------------------------------------------------------------------------- CUSIP NO. 64124E106 13D Page 5 of 10 Pages - -------------------------------------------------------------------------------- final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws, or finding any violations with respect to such laws. Item 3. Source and Amount of Funds or Other Consideration. ------------------------------------------------- All funds used to purchase the securities reported in Item 5 below were provided from the working capital of FP. The aggregate purchase price of such securities was approximately $12,380,478. Item 4. Purpose of Transaction. ---------------------- The securities purchased by FP were purchased solely for investment. FP expects that it will, from time to time, review its investment position in the Issuer and may, depending on market and other conditions, increase or decrease such investment position. FP has no intention of seeking control of the Issuer, nor does it have any plans or proposals with respect to any extraordinary corporate transaction involving the Issuer or any sale of its assets or any change in its Board of Directors, management, capitalization, dividend policy, charter or by-laws, or any other change in its business or corporate structure or with respect to the delisting or deregistration of any of its securities including, without limitation, those matters described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. - -------------------------------------------------------------------------------- CUSIP NO. 64124E106 13D Page 6 of 10 Pages - -------------------------------------------------------------------------------- Item 5. Interest in Securities of the Issuer. ------------------------------------ FP holds 771,900 shares, representing 5.4% of the outstanding shares of Common Stock. (a) Set forth in the table below is the aggregate number of shares of Common Stock beneficially owned as of the date hereof by each person or entity listed in Item 2 above, together with the percentage of outstanding shares of Common Stock which is beneficially owned by each such person or entity. - -------------------------------------------------------------------------------- CUSIP NO. 64124E106 13D Page 7 of 10 Pages - -------------------------------------------------------------------------------- Name of Amount and Nature % of Class Beneficial Owner of Beneficial Ownership Outstanding (1) - ---------------- ----------------------- --------------- Four Partners 771,900 5.4% Andrew H. Tisch 0 (2) 0 1991 Trust Daniel R. Tisch 0 (2) 0 1991 Trust James S. Tisch 0 (2) 0 1991 Trust Thomas J. Tisch 0 (2) 0 1991 Trust Andrew H. Tisch 0 (2) 0 Daniel R. Tisch 0 (2) 0 James S. Tisch 0 (2) 0 Thomas J. Tisch 0 (2) 0 ------- - Total 771,900 5.4% (2) (b) With respect to the persons and entities named in response to paragraph (a) above: (i) FP has directly the sole power to vote or direct the vote and dispose or direct the disposition of the 771,900 shares of Common Stock owned by it; and (ii) By virtue of their status as managing trustees of the trusts which are the general partners of FP, the Messrs. Tisch may be deemed to have indirectly shared power to vote or direct the vote and dispose or direct - ---------- (1) The Issuer's 10-K for the fiscal year ended December 31, 1996 indicated that 14,272,479 shares of Common Stock were issued and outstanding as of March 1, 1997. (2) Does not include shares owned by FP. None of the Messrs. Tisch beneficially owns any shares of Common Stock, except to the extent that beneficial ownership of shares of Common Stock beneficially owned by FP may be attributed to them. - -------------------------------------------------------------------------------- CUSIP NO. 64124E106 13D Page 8 of 10 Pages - ------------------------------------------------------------------------------- the disposition of the 771,900 shares of Common Stock owned by FP. (c) The following transactions were effected by FP during the sixty days preceding the date hereof. None of the persons or entities named in Item 2 above effected any other transactions in the Common Stock during the 60 days preceding the date hereof. Transaction Date Security No. Price/Share Market - ----------- ---- -------- ------- ----------- ------ Purchase 3/6/97 Common 80,000 $17.50 NASDAQ Purchase 3/6/97 Common 200 $17.29 NASDAQ Purchase 3/6/97 Common 500 $17.35 NASDAQ Purchase 3/14/97 Common 2,200 $19.29 NASDAQ Purchase 3/31/97 Common 12,500 $18.77 NASDAQ Purchase 3/31/97 Common 2,000 $18.79 NASDAQ Purchase 4/1/97 Common 3,000 $18.04 NASDAQ Purchase 4/2/97 Common 32,000 $15.71 NASDAQ Purchase 4/3/97 Common 24,000 $14.36 NASDAQ Purchase 4/8/97 Common 4,000 $13.91 NASDAQ Purchase 4/9/97 Common 2,000 $14.04 NASDAQ Purchase 4/10/97 Common 35,400 $14.29 NASDAQ Purchase 4/11/97 Common 10,000 $14.37 NASDAQ Purchase 4/14/97 Common 14,800 $14.41 NASDAQ Purchase 4/15/97 Common 33,200 $14.45 NASDAQ Purchase 4/17/97 Common 2,500 $14.87 NASDAQ Purchase 4/18/97 Common 5,000 $14.88 NASDAQ - -------------------------------------------------------------------------------- CUSIP NO. 64124E106 13D Page 9 of 10 Pages - -------------------------------------------------------------------------------- Item 6. Contracts, Arrangements, Understandings or Relationships with Respect --------------------------------------------------------------------- to Securities of the Issuer. --------------------------- None of the persons or entities named in Item 2 above has any express contracts, arrangements or understandings with any of the other persons or entities named in Item 2 above with respect to the securities of the Issuer. Except as set forth in this Schedule 13D, none of the persons or entities named in Item 2 above has any contracts, arrangements, understandings or relationships with any other person with respect to the securities of the Issuer. None of the persons or entities named in Item 2 above has any contracts, arrangements, understandings or relationships with the Issuer. Item 7. Material to be filed as Exhibits. -------------------------------- None. ---- - -------------------------------------------------------------------------------- CUSIP NO. 64124E106 13D Page 10 of 10 Pages - -------------------------------------------------------------------------------- SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I hereby certify that the information set forth in this statement is true, complete and correct. April 21, 1997 FOUR PARTNERS By /s/ Thomas J. Tisch ---------------------- Thomas J. Tisch Manager of Four Partners -----END PRIVACY-ENHANCED MESSAGE-----